{"id":"intravenous-iclaprim","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Phlebitis at infusion site"}]},"_chembl":{"chemblId":"CHEMBL134561","moleculeType":"Small molecule","molecularWeight":"354.41"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Iclaprim binds to bacterial dihydrofolate reductase with high affinity, blocking the conversion of dihydrofolate to tetrahydrofolate, which is essential for one-carbon transfer reactions and nucleotide synthesis. This mechanism is bacteriostatic and selective for bacterial DHFR over human DHFR, making it suitable for treating bacterial infections. The drug has activity against a broad spectrum of gram-positive and some gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).","oneSentence":"Iclaprim is a dihydrofolate reductase (DHFR) inhibitor that disrupts bacterial folate metabolism, preventing DNA synthesis and bacterial growth.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:16:46.860Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Complicated skin and soft tissue infections (cSSTI)"},{"name":"Hospital-acquired bacterial pneumonia (HABP) / Ventilator-associated bacterial pneumonia (VABP)"}]},"trialDetails":[{"nctId":"NCT02607618","phase":"PHASE3","title":"Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2","status":"COMPLETED","sponsor":"Motif Bio","startDate":"2015-11","conditions":"Skin Structures and Soft Tissue Infections","enrollment":613},{"nctId":"NCT02600611","phase":"PHASE3","title":"Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-1","status":"COMPLETED","sponsor":"Motif Bio","startDate":"2015-11-01","conditions":"Skin Structures and Soft Tissue Infections","enrollment":600},{"nctId":"NCT00543608","phase":"PHASE2","title":"Clinical Efficacy of Intravenous Iclaprim Versus Vancomycin in the Treatment of Hospital-Acquired, Ventilator-Associated, or Health-Care-Associated Pneumonia","status":"TERMINATED","sponsor":"Arpida AG","startDate":"2007-11","conditions":"Hospital-Acquired Pneumonia, Ventilator-Associated Pneumonia, Health-Care-Associated Pneumonia","enrollment":135},{"nctId":"NCT00299520","phase":"PHASE3","title":"Phase 3 Safety and Efficacy Study of I.V. Iclaprim v Linezolid in cSSSI (ASSIST-1)","status":"COMPLETED","sponsor":"Arpida AG","startDate":"2005-06","conditions":"Complicated Skin and Skin Structure Infection","enrollment":""},{"nctId":"NCT00303550","phase":"PHASE3","title":"Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2)","status":"COMPLETED","sponsor":"Arpida AG","startDate":"2006-03","conditions":"Skin Diseases, Bacterial","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":17,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Intravenous iclaprim","genericName":"Intravenous iclaprim","companyName":"Arpida AG","companyId":"arpida-ag","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Iclaprim is a dihydrofolate reductase (DHFR) inhibitor that disrupts bacterial folate metabolism, preventing DNA synthesis and bacterial growth. Used for Complicated skin and soft tissue infections (cSSTI), Hospital-acquired bacterial pneumonia (HABP) / Ventilator-associated bacterial pneumonia (VABP).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}